Celularity IncCELU
Price (close)
$1.38
Market cap
$39.8M
P/E
—
Revenue (TTM)
$26.6M
Net income
-$91.7M
Dividend yield
—
1-year total return
-32.4%
Net margin
-345.4%
Revenue growth
-51.0%
Debt / equity
—
What Celularity Inc does.
company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies
derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and
severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $14.3M | $21.3M | $18.0M | $22.8M | $54.2M | $26.6M |
| Net income | -$208.2M | -$100.1M | $14.2M | -$196.3M | -$57.9M | -$91.7M |
| Free cash flow | -$91.0M | -$116.3M | -$143.1M | -$39.7M | -$6.6M | — |
More on CELU.
- Celularity Inc summary
- Celularity Inc financial statements
- Celularity Inc key metrics
- Celularity Inc health scores and style box
- Celularity Inc earnings
- Celularity Inc dividends
- Celularity Inc valuation
- Celularity Inc ownership and insiders
- Celularity Inc peers
Figures from Celularity Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.